OncoMed initiated a Phase I/II trial of its anti-RSPO3 antibody (OMP-131R10) in patients with relapsed colorectal cancer. Patients will also be receiving FOLFIRI (5-FU, irinotecan, leucovorin). Continue reading
Tag Archives: beta-catenin
Rexahn – 3 Novel Cancer Products in Development
I attended the Rexahn presentation at the Biotech Showcase on January 12-14, 2015. The company has 3 novel anti-cancer products in the clinic. Continue reading
OncoMed’s Wnt-targeted experimental cancer drugs and bone-related adverse events
OncoMed is a biotech company that is developing therapies directed at the Wnt and Notch signaling pathways. Clinical studies with two products directed at the Wnt pathway (Vantictumab – anti-Fzd-7, and Fzd-8 Fc) have been halted by the company while it explores findings of bone toxicity. Continue reading